<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060086</url>
  </required_header>
  <id_info>
    <org_study_id>11-001265</org_study_id>
    <secondary_id>UCLA-0210049</secondary_id>
    <secondary_id>CDR0000299439</secondary_id>
    <nct_id>NCT00060086</nct_id>
  </id_info>
  <brief_title>Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer</brief_title>
  <official_title>Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of&#xD;
      prostate-specific antigen (PSA) levels and may be effective in delaying or preventing&#xD;
      recurrent prostate cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well pomegranate juice works in decreasing or&#xD;
      slowing the rise of PSA levels in patients who have undergone radiation therapy or surgery&#xD;
      for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether pomegranate juice can decrease or slow rising prostate-specific&#xD;
           antigen (PSA) levels in patients who have undergone radical prostatectomy or&#xD;
           radiotherapy for adenocarcinoma of the prostate.&#xD;
&#xD;
      OUTLINE: Patients receive oral pomegranate juice once daily. Treatment continues for 18&#xD;
      months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 29-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2004</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy, in terms of overall response rate, measured by serum prostate-specific antigen (PSA) levels every 3 months</measure>
    <time_frame>Evaluated every 3 months for 18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Pomegranate Juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>pomegranate juice</intervention_name>
    <description>Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Pomegranate Juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Must have undergone prior surgery or radiotherapy for the primary tumor&#xD;
&#xD;
          -  Documented rising prostate-specific antigen (PSA) level, defined by the following&#xD;
             criteria:&#xD;
&#xD;
          -  Absolute level of PSA at least 0.2 ng/mL but less than 5.0 ng/mL&#xD;
&#xD;
          -  Rising PSA level must be confirmed at least 1 week later&#xD;
&#xD;
          -  Adequate PSA time points to calculate a PSA doubling time&#xD;
&#xD;
          -  Gleason score no greater than 7&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  Performance status ECOG 0-1&#xD;
&#xD;
          -  Life expectancy at least 6 months&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  No other serious concurrent systemic medical disorders that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  No known allergy to pomegranate juice&#xD;
&#xD;
          -  More than 4 weeks since prior participation in another experimental study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  nodal involvement&#xD;
&#xD;
          -  evidence of metastatic disease&#xD;
&#xD;
          -  prior hormonal therapy&#xD;
&#xD;
          -  concurrent hormonal therapy for rising PSA levels after initial therapy for prostate&#xD;
             cancer&#xD;
&#xD;
          -  concurrent participation in another experimental study&#xD;
&#xD;
          -  other concurrent systemic or local therapy for prostate cancer&#xD;
&#xD;
          -  initiation or discontinuation of any new nutritional or dietary supplements during&#xD;
             study participation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Pantuck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

